Pharmaceutical - CNS Diseases

Filter

Current filters:

CNS Diseases

Popular Filters

Sarepta receives new FDA guidance on data needed for eteplirsen's NDA in Duchenne Muscular Dystrophy

Sarepta receives new FDA guidance on data needed for eteplirsen's NDA in Duchenne Muscular Dystrophy

28-10-2014

Rare and infectious disease specialist Sarepta provided an update on its discussions with the US Food…

CNS DiseaseseteplirsenPharmaceuticalRegulationSarepta TherapeuticsUSA

GW Pharmaceuticals granted orphan designation by the EMA for Epidiolex

GW Pharmaceuticals granted orphan designation by the EMA for Epidiolex

22-10-2014

Cannabinoid product specialist GW Pharmaceuticals has been granted orphan designation by the European…

CNS DiseasesepidiolexGW PharmaceuticalsPharmaceuticalResearchUSA

FDA accepts Eisai's supplemental New Drug Application for Fycompa in tonic-clonic seizures

FDA accepts Eisai's supplemental New Drug Application for Fycompa in tonic-clonic seizures

20-10-2014

Japanese drug major Eisai has had a supplemental New Drug Application for its in-house-discovered AMPA…

CNS DiseasesEisaiFycompaJapanPharmaceuticalRegulation

FDA accepts NDA filing for Lundbeck and Otsuka's brexpiprazole

FDA accepts NDA filing for Lundbeck and Otsuka's brexpiprazole

24-09-2014

The US Food and Drug Administration has accepted the filing for review of brexiprazole for the treatment…

CNS DiseasesLundbeckOtsukaPharmaceuticalRegulationUSA

PTC Therapeutics establishes international headquarters in Dublin, appoints Adrian Haigh head of EMEA

PTC Therapeutics establishes international headquarters in Dublin, appoints Adrian Haigh head of EMEA

17-09-2014

USA-based PTC Therapeutics is to expand its global presence by adding key executives to leadership positions…

BoardroomCNS DiseasesIrelandPharmaceuticalPTC TherapeuticsTranslarna

Lundbeck launches Brintellix in Denmark

Lundbeck launches Brintellix in Denmark

16-09-2014

Danish CNS drug specialist Lundbeck is debutting its new antidepressant Brintellix (vortioxetine) in…

BrintellixCNS DiseasesDenmarkLundbeckMarkets & MarketingPharmaceutical

Avanir shares jump 85% on positive AVP-923 clinical trial results

Avanir shares jump 85% on positive AVP-923 clinical trial results

16-09-2014

US CNS specialist Avanir Pharmaceuticals has announced positive results from the Phase II clinical trial…

AvanirAVP-923CNS DiseasesPharmaceuticalResearchUSA

MS market to reach $20 billion in 2023 boosted by five new therapies

MS market to reach $20 billion in 2023 boosted by five new therapies

08-08-2014

The forecast launch of five immunomodulatory therapies for relapsing forms of multiple sclerosis will…

CNS DiseasesEuropeImmunosuppressantsJapanMarkets & MarketingMSPharmaceuticalUSA

Biogen and AbbVie release Phase III data for MS treatment

Biogen and AbbVie release Phase III data for MS treatment

17-06-2014

US biotech firm Biogen Idec and US drugmaker AbbVie have announced positive top-line results from the…

AbbVieBiogen IdecCNS DiseasesdaclizumabPharmaceuticalResearchUSA

US FDA grants Edison Pharmaceuticals’ EPI-743 orphan status for Leigh Syndrome

US FDA grants Edison Pharmaceuticals’ EPI-743 orphan status for Leigh Syndrome

09-06-2014

The US Food and Drug Administration has granted orphan drug status to privately-held US pharma company…

CNS DiseasesEdison PharmaceuticalsEPI-743PharmaceuticalRegulationUSA

Pfizer agrees to pay $325 million over Neurontin

Pfizer agrees to pay $325 million over Neurontin

03-06-2014

US pharma giant Pfizer has agreed a $325 million settlement over a trial regarding the marketing of Neurontin…

CNS DiseasesLegalNeurontinPfizerPharmaceuticalUSA

Lundbeck partners with Nanomerics for drug delivery collaboration

Lundbeck partners with Nanomerics for drug delivery collaboration

30-04-2014

UK-based drug delivery company Nanomerics, a spin out of the University College London, has announced…

Brain cancerBrain tumorCNS DiseasesDementiaLundbeckMedicineNeurologicalPharmaceuticalResearchUKUniversity College London

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

16-04-2014

Surveyed neurologists in France, Germany, Italy, Spain and the UK project that 16% of their diagnosed…

AubagioBiogen IdecChemistryCNS DiseasesEuropeGenzymeMajorPharmaceuticalPharmacologyPhysicianResearchSANTecfidera

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

21-01-2014

US drugmaker Forest Laboratories (NYSE: FRX) released its third quarter 2013/14 results today showing…

CNS DiseasesFinancialForest LaboratoriesPharmaceuticalRespiratory and PulmonaryUSA

Forest Laboratories announces new appointments to its executive team

16-12-2013

New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

Sativex approved for MS in Switzerland

Sativex approved for MS in Switzerland

27-11-2013

UK-based GW Pharmaceuticals (AIM: GWP), which is focused on novel cannaboid therapeutics, has received…

AlmirallCNS DiseasesEuropeGW PharmaceuticalsPharmaceuticalRegulationSativex

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

19-11-2013

UK-based GW Pharmaceuticals (AIM: GWP) which is focused on novel cannaboid therapeutics, has announced…

CNS DiseasesFinancialGW PharmaceuticalsPharmaceuticalSativexUK

Sanofi’s Lemtrada gets support from FDA advisory panel

Sanofi’s Lemtrada gets support from FDA advisory panel

14-11-2013

French drug major Sanofi (Euronext: SAN) has received support from a US Food and Drug Administration…

CNS DiseasesEuropeGenzymeLemtradaPharmaceuticalRegulationSanofi

Novartis MS drug Gilenya leads to reduction in brain volume drug

Novartis MS drug Gilenya leads to reduction in brain volume drug

04-10-2013

Novartis has revealed new data indicating that continued treatment with Gilenya led to a reduction in…

CNS DiseasesEuropeGilenyaNovartisPharmaceuticalResearch

Parexel

Parexel

Back to top